Alector | Therapies to Remember
Slide background

We are a biotech company dedicated to the discovery and development of first-in-class, disease-modifying, immuno-modulatory therapies for dementia and neurodegeneration.

Slide background

"Excellence is never an accident. It is always the result of high intention, sincere effort, and intelligent execution; it represents the wise choice of many alternatives – choice, not chance, determines your destiny.”
- Aristotle

Our Mission

To discover and develop first-in-class, disease-modifying,
immuno-modulatory therapies for dementia and neurodegeneration

About Alector

Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration. Our strategy is to efficiently generate and validate antibody drugs that engage key disease-altering, genetically-validated neuro-immune targets. Alector’s approach is enabled by a strategic alliance with Adimab, the technology leader in the discovery of fully human antibodies and bispecifics.

  • OrbiMed
  • Polaris
  • Merck
  • Google
  • Topspin
  • Mission Bay Capital


Thought leaders in biotechnology, neuroscience, and antibody drug discovery

  • All
  • Board
  • Founders
  • Investors
  • Operations
  • SAB
  • Scientists

Co-Founder, President, CSO, Board Member, Chairman of Scientific Advisory Board - Rinat Neuroscience Corp. (acquired by Pfizer in 2006)

Co-Founder, Board Member - Annexon Inc.

Member of Scientific Advisory Board - Simons Foundation Autism Research Initiative

Member of Scientific Advisory Board - Myelin Repair Foundation

Former Member of Scientific Advisory Board for Neuroscience - UCB Pharma

Executive Scientist, Member of the Research Review Committee - Genentech Inc.

Arnon Rosenthal, PhD
Co-Founder, CEO, President

Co-Founder - ShanaRX Pharmaceuticals

Postdoctoral Researcher - Genentech Inc.

Tenured Associate Professor - Taub Institute at Columbia University, Departments of Pathology and Neurology

Diplomate in Neurology - American Board of Psychiatry and Neurology

Asa Abeliovich, MD PhD
Co-Founder, SAB Member

Co-Founder, CEO - Adimab LLC

Co-Founder, Chairman of the Board - Arsanis Inc.

Co-Founder, Chairman of the Board - Avitide Inc.

Co-Founder, CSO - GlycoFi (acquired by Merck in 2006)

Professor of Bioengineering - Dartmouth College

Venture Partner - SV Life Sciences

Tillman Gerngross, PhD
Co-Founder, Chairman of the Board

Scientist - Sutro Biopharma

Postdoctoral Research Fellow and Research Associate - Memorial Sloan-Kettering Cancer Center, Department of Immunology

Doctoral Research Scientist - European Institute of Oncology (Italy) and University of Cambridge (UK)

Francesca Avogadri-Connors, PhD
Lead Scientist - Neuroimmunology; Cell & In Vivo Biology
Ben Barres

Ben Barres
SAB Member

Adam Boxer, MD PhD
SAB Member
Paul Crocker

Paul Crocker, FRSE
SAB Member

Founding Partner, Co-Head of Global Private Equity - OrbiMed

Senior Biotechnology Analyst - Mehta and Isaly

Fellow - The Rockefeller University

Carl Gordon, PhD CFA
Board Member, Investor

Director of Manager Research - North Creek Advisors

Senior Associate - The Parthenon Group

Analyst - Dean & Company

Kelly Hackett
General Manager

Lab Manager - Dartmouth College

10+ years experience working in academic and industrial labs

Experience in GMP environments

Helped set up 3 new labs from start to finish

Heather Jewell
Lab Manager

MS, Biomedical Science, Concentration in Biotechnology - San Francisco State University

BS, Biochemistry and Molecular Biology - University of California, Davis

Helen Lam
Research Associate - Cell Biology
Lewis Lanier

Lewis Lanier, PhD
SAB Member
Seung-Joo Lee

Staff Research Associate - University of California, Davis

Postdoctoral Associate - University of California, Davis

PhD Immunology - University of Connecticut Health Center

Seung-Joo Lee, PhD
Associate Scientist

Co-Founder, General Partner - Polaris Partners

Co-Founder - Inspire Pharmaceuticals, AIR, MicroCHIPS

Chairman of the Board - Thayer School of Engineering, Dartmouth College

Board Member - MIT’s The David H. Koch Institute for Integrative Cancer Research

Board Member - The Arthur Rock Center for Entrepreneurship at HBS

2005 Recipient - Albert Einstein Award for Outstanding Achievement in Life Sciences

Terry McGuire
Board Member, Investor
Bruce Miller

Bruce Miller, MD
SAB Member

Postdoctoral Research Fellow - Gladstone Institute of Virology and Immunology

Doctoral Research - University of California Berkeley, Program in Cell and Molecular Biology

Research Technician - University of Utah, Department of Human Genetics

Kate Monroe, PhD
Lead Scientist - Neuroimmunology & Cell Biology

Graduate Research Assistant - University of North Carolina

Graduate Research Assistant - East Carolina University

PhD Chemistry - University of North Carolina, Chapel Hill

William Monteith, PhD
Associate Scientist - Protein Biochemistry

Postdoctoral Fellow - The Rockefeller University

Graduate Research Assistant - Northwestern University

Andrew Pincetic, PhD
Lead Scientist - Protein Biochemistry & Engineering
Josh Resnick

President and Managing Partner - MRL Ventures, Merck

Founder, Founding President - Surface Oncology

Founder, Founding President and CEO - Ataxion

Venture Partner - Atlas Venture

Attending Physician, Department of Emergency Medicine - Massachusetts General Hospital

Instructor - Harvard Medical School

Josh Resnick, MD
Board Member, Investor
Richard Scheller

Richard Scheller, PhD
SAB Member

Postdoctoral Research Fellow and Research Associate - Stanford University, Department of Neurobiology

Postdoctoral Research Fellow - Rockefeller University

Doctoral Research Scientist - Rockefeller University and University of Hohenheim, Germany

Tina Schwabe, PhD
Lead Scientist - Neurogenetic & Cell Biology

Co-Founder, Director of Finance & Operations - Avitide Inc.

Director of Finance & Operations - Arsanis Inc.

Bain Capital Ventures

McKinsey & Company

Founder - Bedrock Ventures

Jonathan Sheller
Director of Finance & Operations

Research Fellow - National Institute of Health, Laboratory of Molecular Immunology

Postdoctoral Research Fellow - Washington University, Department of Pathology

Doctoral Research Scientist - Washington University and La Sapienza University of Rome, Department of Experimental Medicine

Ilaria Tassi, PhD
Lead Scientist - Neuroimmunology; Cell Signaling & In Vivo Biology
Robert Vassar

Robert Vassar, PhD
SAB Member

OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over $15 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed's team of more than 90 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.


Polaris Partners invests in exceptional technology and healthcare companies across all stages of their life cycles. With offices in Boston, San Francisco, and Dublin, we partner globally with an unparalleled network of repeat entrepreneurs, top scientists and emerging innovators who are making significant contributions in their fields and vastly improving the way in which we live and work.

Polaris Partners

MRL Ventures Fund, LLC is the therapeutics-focused seed and early-stage corporate venture fund of Merck & Co., Inc. From our headquarters in Kendall Square, Cambridge and with offices in Mission Bay, San Francisco and Central London, MRL Ventures invests globally in innovative science and transformational therapeutics. We are a team of experienced life-sciences venture capital professionals committed to supporting great entrepreneurs in their quest to create value through building companies that have a meaningful impact on health and disease.

MRL Ventures

Google Ventures

Topspin Partners is a private equity firm that focuses on control investments in lower middle-market companies with $2 million to $10 million of EBITDA. We seek to acquire companies that are both defensible and differentiated – that is, (1) the business has characteristics that enable it to compete in the marketplace other than by simply lowering price and (2) its products or services provide a different and, in many cases, unique approach to addressing an existing market need.

Topspin Partners
Mission Bay Capital

Mission Bay Capital (MBC) is an independent, seed-stage venture firm focused on making pivotal investments in bioscience companies emerging from the San Francisco Bay Area. MBC combines experienced management and a stellar advisory board with access to life-science accelerator QB3’s entrepreneurial network: University of California researchers, scientific facilities, and incubators at five locations including the San Francisco flagship, QB3@953. MBC’s goal is to “enable awesome”—to help entrepreneurial scientists change the world.

Mission Bay Capital

Neurodegenerative Diseases



Americans living with




leading cause of death

in the US



direct cost of caring for

Alzheimer’s patients to US

Alzheimer’s disease is the most common form of dementia, affecting over 5 million people in the US alone. It is characterized by gradual mental deterioration, loss of memory, and eventually death (it is the 6th-leading cause of death in the US). AD is a high-profile disease with diagnosis incidence rates expected to rise rapidly due to demographic trends. 11% of those over 65 have been diagnosed with Alzheimer’s. There are currently no methods to prevent, cure, or meaningfully slow its progression. In 2011, the Alzheimer’s disease drug market was a $5.8B. It is expected to grow to $14.5B by 2020 (excluding novel treatments and all other forms of dementia). The cost of care for Alzheimer’s is estimated to grow from $203B in 2013, to $1.2T in 2050. Other forms of dementia including frontotemporal dementia, are less common, with 100K-200K patients in the US, and are thus considered orphan diseases. No therapeutics have been shown to alter the inexorable courses of these disorders.

What Others Are Saying About Alzheimer’s

It’s an epidemic, it’s on the rise, and currently there is no way to delay it, prevent it or cure it.

– Maria Carrillo, PhD (Alzheimer’s Association)

If dementia care were a country, it would be the world’s 21st largest economy, ranking between Poland and Saudi Arabia.

– Alzheimer’s Association

We’ve had great success in this country when we’ve decided to focus on a condition. We’ve done it with good research in heart disease, cancer and HIV, but we are in our infancy when it comes to Alzheimer’s research.

– Jennifer Weuve, MPH ScD (Assistant Professor, Rush Medical College)

Recent News

  • FierceBiotech’s 2015 Fierce 15 – Alector

    Alector Bringing the principles of immuno-oncology to Alzheimer’s CEO: Arnon Rosenthal Based: San Francisco Founded: 2013 Clinical focus: Neurodegenerative disease Company website The scoop: Developing drugs for Alzheimer’s disease, a daunting task, has lately focused on toxic proteins that accumulate in the brain. Which to......

    30 Sep 2015
  • Google, OrbiMed buy into Alector’s novel take on Alzheimer’s with a $32M round

    Under-the-radar biotech startup Alector raised $32 million in Series C funds to support its early-stage work in neurodegenerative disease, recruiting some high-profile investors as it develops a novel approach to brain-destroying disorders. The latest funds come courtesy of lead investor MRL Ventures, joined by new......

    16 Sep 2015
  • Alector Raises $32M For Immune-Based Neuro Drug Development

    Researchers around the world have explored the ties between the immune system and devastating neurodegenerative diseases such as Alzheimer’s. San Francisco biotech Alector wants to exploit those ties to make drugs, and today it announced $32 million in venture funding—with another round likely coming by......

    16 Sep 2015